Ligand id: 9592

Name: tislelizumab

Compound class Antibody
Ligand families/groups Immune checkpoint modulators
International Nonproprietary Names
INN number INN
10553 tislelizumab
BGB-A317 | BGBA317 | hu317-1/IgG4mt2
Tislelizumab (BGB-A317) is a humanized IgG4 monoclonal antibody targeting the PD-1 immune checkpoint [3]. It contains an alternative hinge region compared to other IgG4 anti-PD-1 antibodies, and subsequently does not induce the crosslinking between PD-1 and FcγRI that is observed for existing agents and which is believed to negatively impact on anti-PD-1 antibody-mediated anti-cancer activity. This modified profile is predicted to enhance tislelizumab's clinical efficacy [3]. Like other anti-PD-1 antibodies tislelizumab acts to prevent the binding of the ligands PD-L1 and PD-L2 to PD-1. Tislelizumab is an immuno-oncology drug candidate being developed by Beigene Ltd (see their patent US8735553B1 [2]).
Database Links
GtoPdb PubChem SID 340590223
Search PubMed clinical trials tislelizumab
Search PubMed titles tislelizumab
Search PubMed titles/abstracts tislelizumab